Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $3.33 USD
Change Today +0.17 / 5.38%
Volume 724.3K
CPRX On Other Exchanges
Symbol
Exchange
NASDAQ CM
As of 8:10 PM 05/1/15 All times are local (Market data is delayed by at least 15 minutes).

catalyst pharmaceutical part (CPRX) Snapshot

Open
$3.24
Previous Close
$3.16
Day High
$3.44
Day Low
$3.20
52 Week High
03/19/15 - $5.10
52 Week Low
05/9/14 - $1.70
Market Cap
272.5M
Average Volume 10 Days
2.2M
EPS TTM
$-0.24
Shares Outstanding
81.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CATALYST PHARMACEUTICAL PART (CPRX)

Related News

No related news articles were found.

catalyst pharmaceutical part (CPRX) Related Businessweek News

No Related Businessweek News Found

catalyst pharmaceutical part (CPRX) Details

Catalyst Pharmaceutical Partners, Inc., a development-stage biopharmaceutical company, focuses on the development and commercialization of prescription drugs targeting rare (orphan) neurological diseases and disorders. The company offers Firdapse, a proprietary form of amifampridine phosphate, which is in Phase III clinical trial for the treatment of Lambert-Eaton Myasthenic Syndrome. It is also involved in the development of CPP-115, a GABA aminotransferase inhibitor, which is in Phase Ib clinical trial for the treatment of epilepsy and other selected neurological indications, such as complex partial seizures and Tourette Syndrome; and CPP-109 for the treatment of Tourette Syndrome. Catalyst Pharmaceutical Partners, Inc. has a strategic collaboration agreement with BioMarin Pharmaceutical, Inc. The company was founded in 2002 and is based in Coral Gables, Florida.

12 Employees
Last Reported Date: 03/13/15
Founded in 2002

catalyst pharmaceutical part (CPRX) Top Compensated Officers

Co-Founder, Chairman, Chief Executive Officer...
Total Annual Compensation: $426.5K
Chief Financial Officer, Chief Accounting Off...
Total Annual Compensation: $231.0K
Chief Operating Officer and Chief Scientific ...
Total Annual Compensation: $309.4K
Compensation as of Fiscal Year 2013.

catalyst pharmaceutical part (CPRX) Key Developments

Catalyst Pharmaceutical Partners Inc. Proposes Amendment to Certificate of Incorporation

Catalyst Pharmaceutical Partners Inc. proposed amendment to Certificate of Incorporation that would increase the number of authorized shares of common stock from 100,000,000 shares to 150,000,000 shares and change corporate name from Catalyst Pharmaceutical Partners Inc. to Catalyst Pharmaceuticals Inc., at the annual meeting of stockholders to be held on May 21, 2015.

Catalyst Pharmaceutical Partners Inc. Announces Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014

Catalyst Pharmaceutical Partners Inc. announced earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company reported a GAAP net loss of $3,490,030, or $0.05 per basic and diluted share, compared to a GAAP net loss of $1,354,658, or $0.03 per basic and diluted share, for the 2013 fiscal year. Excluding non-cash income of $472,026 attributable to the change in fair value of liability-classified warrants, Non-GAAP net loss was $3,962,056 or $0.06 per basic and diluted share for the fourth quarter of 2014. In comparison, Non-GAAP net loss for the fourth quarter of 2013 was $2,684,813, or $0.05 per basic and diluted share, which excludes non-cash income of $1,330,155 attributable to the change in fair value of liability-classified warrants. For the full year, the company reported a GAAP net loss of $15,509,061, or $0.24 per basic and diluted share, compared to a GAAP net loss of $12,154,596, or $0.27 per basic and diluted share, for the 2013 fiscal year. Excluding non-cash expense of $993,866 attributable to the change in fair value of liability-classified warrants, Non-GAAP net loss was $14,515,195, or $0.23 per basic and diluted share for the year ended December 31, 2014. In comparison, Non-GAAP net loss for the year ended December 31, 2013 was $10,264,237, or $0.23 per basic and diluted share, which excludes non-cash expense of $1,890,359 attributable to the change in fair value of liability-classified warrants. Loss from operations was $14,591,428 compared to $10,311,658 a year ago. Loss before income tax was $15,509,061 compared to $12,154,596 a year ago.

Catalyst Pharmaceutical Partners, Inc. Announces FDA Orphan Drug Designation of Firdapse

Catalyst Pharmaceutical Partners Inc. announced that the U.S. Food and Drug Administration (FDA) has granted the company orphan drug designation for Firdapse for treatment of patients with Congenital Myasthenic Syndromes (CMS). CMS is a rare neuromuscular disease comprising a spectrum of genetic defects and is characterized by fatigable weakness of skeletal muscles with onset at or shortly after birth or early childhood; in rare cases symptoms may not manifest themselves until later in childhood. The severity and course of the disease are variable, ranging from minor symptoms to progressive disabling weakness; symptoms may be mild, but sudden severe exacerbations of weakness or even sudden episodes of respiratory insufficiency also occur. Catalyst also confirmed that it has received the formal minutes from the FDA reporting on the discussions at its pre-new drug application (NDA) meeting held earlier this year and that the minutes of the meeting confirm the information about the results of the meeting previously reported by Catalyst. On February 2, 2015, Catalyst reported that it had held a productive pre-NDA meeting with the FDA regarding Firdapse for the treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) and that, based on the discussions at that meeting, Catalyst believes that its Phase 3 clinical program will provide acceptable support for submission of an NDA for Firdapse for LEMS. Catalyst also reported that potential paths forward for one type of congenital myasthenic syndromes were also discussed at the meeting.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CPRX:US $3.33 USD +0.17

CPRX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CPRX.
View Industry Companies
 

Industry Analysis

CPRX

Industry Average

Valuation CPRX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 6.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CATALYST PHARMACEUTICAL PART, please visit www.catalystpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.